The British Pharmacopoeia 2019 supersedes the British Pharmacopoeia 20 18. It has been prepared by the British Pharmacopoeia
The British Pharmacopoeia 2019 supersedes the British
Pharmacopoeia 20 18. It has been prepared by the British Pharmacopoeia Commission,
with the collaboration and support of its Expert Advisory Groups, Panels of Experts
and Working Parties and contains approximately 4000 monographs for substances, preparations
and articles used in the practice of medicine. Some of these monographs are of national
origin and have been elaborated or revised under the auspices of the British
Pharmacopoeia Commission whilst others (indicated to users by a chaplet of
stars) have been elaborated, or revised, under the auspices of the European
Pharmacopoeia Commission, supported by its Groups of Experts and Working
Parties, and are reproduced from the European Pharmacopoeia. This edition, together
with its companion volume, the British Pharmacopoeia (Veterinary) 2019, incorporates
all the monographs of the 9th Edition of the European Pharmacopoeia, as amended
by Supplements 9.1 to 9.5 . Users of the British Pharmacopoeia thereby benefit by
finding within this comprehensively indexed compendium all current United Kingdom
pharmacopoeial standards for medicines for human use.
The British Pharmacopoeia
Commission has caused this British Pharmacopoeia 2019 to be prepared under
regulation 3 17(1) af the Human Medicines Regulations 2012 and) in accordance
with regulation 3 17 (4), the Ministers have arranged for it to be published.
It has been notified in draft ro the European Commission in accordance with
Directive 98/341EEC. The monographs of the Ninth Edition of the European
Pharmacopoeia (2016), as amended by Supplements 9.1 to 9.5, published by the
Council of Europe are reproduced either in this edition of the British Pharmacopoeia
or in the associated edition of the British Pharmacopoeia (Veterinary).
Contents of Volume I
FOREWORD
NOTICES
PREFACE
BRITISH PHARMACOPOEIA
COMMISSION
EXPERT ADVISORY GROUPS,
PANELS OF EXPERTS AND
WORKJNG PARTIES
CODE OF PRACTICE
MEMBERSHIP
BP Commission, Expert
Advisory Groups, Panels of Experts, Working
Parties
STAFF
British Pharmacopoeia, BP
Laboratory, Publisher
INTRODUCTION
Additions, Omissions, Technical
Changes, Changes in Title
GENERAL NOTICES
MONOGRAPHS
Medicinal and Pharmaceutical
Substances (A - I)
Contents ofVolurne II
NOTICES
GENERAL NOTICES
MONOGRAPHS
Medicinal and Pharmaceutical
Substances a - Z)
Contents of Volume III
NOTICES
GENERAL NOTICES
MONOGRAPHS
Formulated Preparations:
General Monographs
Formulated Preparations:
Specific Monographs
Contents of Volume IV
NOTICES
GENERAL
NOTICES
MONOGRAPHS
Herbal Drugs, Herbal Drug Preparations and Herbal Medicinal Products
Materials for use in the Manufacture of Homoeopathic Preparations
Blood-related Products
Immunological Products
Radiopharmaceutical Preparations
Surgical Materials
Contents of Volume V
NOTICES
GENERAL
NOTICES
INFRARED
REFERENCE SPECTRA
APPENDICES
SUPPLEMENTARY
CHAPTERS
INDEX
The British Phannacopoeia Commission has caused this British
Pharmacopoeia 2019 to be prepared under regulation 317 (1) of the Human Medicines
Regulations 2012 and, in accordance with regulation 317(4), the Ministers have
arranged for it to be published. The British Phannacopoeia 2019 contributes
significantly to the quality control of medicinal products for human use. It contains
publicly available, legally enforceable standards that provide an authoritative
statement of the quality that a product, material or article is expected to meet
at any time during its period of use. The Pharmacopoeial standards are designed
to complement and assist the licensing and inspection processes and are part of
the overall system for safeguarding purchasers and users of medicinal products in the UK. The British Phannacopoeia
Commission wishes to record its appreciation of
the services of all
those who have contributed to this important work.
%20Web%20of%20pharma%20.webp)
%20webofpharma.JPG)
.png)
